C84.65 Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb

Name of the Condition

• Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb (ICD-10 Code: C84.65)

Summary

Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb (ALCL, ALK-positive) is a rare subtype of non-Hodgkin lymphoma that primarily affects T-lymphocytes. It is characterized by the presence of the anaplastic lymphoma kinase (ALK) protein, resulting from a specific genetic rearrangement. This condition typically presents as a rapidly growing tumor involving the lymph nodes of the inguinal region and lower limb. ALCL, ALK-positive is more common in children and young adults and is generally considered aggressive but responsive to targeted therapies.

Causes

The exact cause of ALK-positive ALCL is not fully understood. The disease is driven by a genetic translocation involving the ALK gene, most commonly the t(2;5)(p23;q35) translocation, which results in overexpression of the ALK protein. This abnormal protein promotes uncontrolled cell growth and survival. While the translocation is a key driver, other genetic mutations may contribute to disease development, though specific environmental triggers remain unclear.

Risk Factors

• Age: More common in children and young adults, with a peak incidence in the second and third decades of life.
• Gender: Slightly higher prevalence in males.
• Genetic factors: Presence of the ALK translocation is a primary risk factor.
• Immunosuppression: Weakened immune systems may increase susceptibility.

Symptoms

Symptoms may include rapidly enlarging lymph nodes in the inguinal region or lower limb, fever, night sweats, unexplained weight loss, fatigue, and skin lesions. Some patients may experience pain or discomfort in the affected areas. Systemic symptoms like fever and weight loss are common in aggressive lymphomas.

Diagnosis

Diagnosis involves a combination of physical examination, imaging studies (e.g., CT or MRI), and biopsy of the affected lymph node. Histopathological analysis confirms the presence of large, anaplastic cells, and immunohistochemistry or molecular testing detects the ALK protein. Staging evaluations assess disease extent.

Treatment Options

Treatment typically includes systemic therapies such as chemotherapy, targeted therapy (e.g., ALK inhibitors), and immunotherapy. Radiation may be used for localized disease. Treatment plans are individualized based on disease stage, patient age, and overall health. Clinical trials may be an option for some patients.

Prognosis and Follow-Up

Prognosis varies but is generally better for ALK-positive ALCL compared to ALK-negative subtypes, especially with early treatment. Regular follow-up with imaging and clinical assessments is essential to monitor for recurrence or progression. Long-term survival is possible with effective therapy.

Complications

Complications may include disease progression, treatment-related side effects (e.g., infection, organ toxicity), and recurrence. Advanced disease can affect organ function or lead to systemic symptoms. Prompt management of complications is critical.

Lifestyle & Prevention

No specific preventive measures exist, as the cause is genetic. Maintaining a healthy immune system through balanced nutrition, regular exercise, and avoiding known immunosuppressants may support overall health. Patients should avoid exposure to infections when immunosuppressed.

When to Seek Professional Help

Seek medical attention for persistent lymph node enlargement, unexplained weight loss, fever, or fatigue. Early evaluation is important for timely diagnosis and treatment. Follow up with a hematologist or oncologist for ongoing care.

Tips for Medical Coders

Use C84.65 for anaplastic large cell lymphoma, ALK-positive, specifically involving lymph nodes of the inguinal region and lower limb. Ensure documentation specifies the site and confirms ALK positivity. Differentiate from other lymphoma codes by verifying the anatomical location and molecular marker.